ECT Special Topics

Study Notes

Sources: Kaplan & Sadock's Synopsis of Psychiatry (12th ed.), Stahl's Essential Psychopharmacology (5th ed.), APA Task Force on ECT (3rd ed.), MHCA 2017, Telemedicine Practice Guidelines 2020 (MoHFW), PG exams ECT Standards

SECTION 1: ELECTROCONVULSIVE THERAPY (ECT)

1.1 Historical Context

ECT was introduced by Ugo Cerletti and Lucio Bini in Rome in 1938. The original theoretical basis (now discredited) was that epilepsy and schizophrenia were biologically incompatible. Prior to electrical induction, camphor and later pentylenetetrazol (Metrazol) were used to induce seizures. ECT remains one of the most effective and fastest-acting treatments in psychiatry, with response rates of 70–90% in severe depression.

1.2 Mechanism of Action

The precise mechanism remains under active investigation. Multiple complementary hypotheses exist:

1.2.1 Anticonvulsant Theory

• ECT raises seizure threshold over the course of treatment (the "anticonvulsant" effect)
• This parallels the mechanism of action of anticonvulsant mood stabilizers
• Increased inhibitory GABAergic activity post-ECT
• Reduction in ictal EEG complexity correlates with therapeutic response
• Supporting evidence: seizure threshold rises, ictal duration shortens across sessions

1.2.2 Neurotrophic / Neuroplasticity Theory

• ECT increases Brain-Derived Neurotrophic Factor (BDNF), particularly in hippocampus and prefrontal cortex
• Stimulates neurogenesis in dentate gyrus (hippocampal neurogenesis)
• Upregulation of VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor)
• This reverses hippocampal volume loss seen in chronic depression
• May explain why cognitive effects are paradoxically less severe than feared, new neurons are generated

1.2.3 Monoamine Hypothesis

• Acute seizures produce massive release of norepinephrine, dopamine, and serotonin
• Downregulation of beta-adrenergic and 5-HT2 receptors after repeated ECT (similar to antidepressants)
• Dopaminergic enhancement may explain antimanic and antipsychotic effects
• ECT also increases dopamine receptor sensitivity in nigrostriatal pathways, relevant in NMS treatment

1.2.4 Neuroendocrine Theory

• ECT normalizes HPA axis hyperactivity
• Reduction in CSF CRH (corticotropin-releasing hormone) levels
• Normalizes dexamethasone suppression test (DST) results in melancholic depression

1.2.5 Anticonvulsant Theory (Advanced)

• Increased enkephalin and endorphin release post-seizure
• Elevated adenosine (an endogenous anticonvulsant) may mediate postictal suppression
• Post-ictal EEG suppression amplitude correlates with therapeutic efficacy

1.2.6 Neuroinflammatory / Immunomodulatory Theory (Emerging)

• ECT reduces pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) in depressed patients
• May be particularly relevant in "immunological" subtypes of depression
• Emerging research links depression severity to neuroinflammatory markers

1.3 Indications for ECT

1.3.1 Primary / First-Line Indications

These are conditions where ECT is appropriate as a first-choice treatment, not just a "last resort":

1.3.2 Secondary Indications (After Failed Pharmacotherapy)

• Treatment-resistant depression (failed 2+ adequate medication trials)
• Bipolar depression (treatment-resistant)
• Schizoaffective disorder with prominent affective symptoms
• Schizophrenia (predominantly for affective and catatonic features)
• Obsessive-compulsive disorder (refractory, limited evidence)
• Status epilepticus (refractory, paradoxically, ECT raises seizure threshold)

1.3.3 ECT in Special Clinical Scenarios

• Pregnancy: ECT is the preferred treatment for severe depression/psychosis in first trimester; safer than most psychotropics for the fetus; requires obstetric monitoring, left lateral decubitus positioning, fetal heart rate monitoring
• Elderly: Generally well-tolerated; lower stimulus doses; higher cognitive monitoring; may need more spaced sessions
• Parkinson's disease: ECT improves both mood and motor symptoms; "on-off" fluctuations respond
• Post-stroke depression: ECT effective; requires cardiac and neurological clearance
• HIV/CNS infections: Relative caution; increased cognitive risk

1.4 Contraindications to ECT

1.4.1 Absolute Contraindications (Very Few)

There are no absolute contraindications in the strict sense, the APA recognizes only conditions requiring extreme caution. However, examiners expect these to be known:

• Pheochromocytoma, catecholamine surge during ECT can be fatal
• Raised intracranial pressure (ICP), seizure further increases ICP; risk of herniation

1.4.2 Relative Contraindications (Risk-Benefit Assessment Required)

• Recent myocardial infarction (within 3 months), increased cardiac risk
• Unstable angina / significant arrhythmias
• Aortic or cerebral aneurysm, rupture risk during BP surge
• Recent stroke (within 3 months), may worsen neurological deficit
• Severe osteoporosis, fracture risk (use adequate muscle relaxant)
• Retinal detachment
• Active pulmonary infection / respiratory compromise
• Space-occupying intracranial lesion (not all, depends on mass effect)
• Anticoagulation (can be managed)

1.5 Pre-ECT Workup

1.5.1 Clinical Assessment

• Detailed psychiatric history confirming indication
• Medical and anesthetic history (prior ECT, complications)
• Medication review (see below)
• Cognitive baseline assessment (Mini-Mental State Examination or similar)
• Consent discussion (see Section 1.10)

1.5.2 Investigations

1.5.3 Medication Management Pre-ECT

1.6 ECT Procedure: Step-by-Step

1.6.1 Pre-procedure Preparation

• NPO (nil per os) for minimum 6–8 hours (solid food), 4 hours (clear liquids), per anesthesia protocol
• IV access established
• Vital signs baseline
• Glycopyrrolate (anticholinergic), 0.2 mg IV, to reduce secretions and bradycardia
• Alternative: atropine 0.3–0.6 mg IV/IM (less preferred due to tachycardia)
• EEG electrodes applied (bitemporal and vertex monitoring electrodes)
• Blood pressure cuff on ankle (isolated limb technique, see below)
• Pulse oximetry, ECG monitoring
• Bite block prepared

1.6.2 Anesthesia

Induction Agents:

Swipe to compare →

Muscle Relaxant:

• Succinylcholine (suxamethonium): 0.5–1.5 mg/kg IV
• Depolarizing neuromuscular blocker
• Onset: 30–60 seconds
• Duration: 5–10 minutes
• Allows modified ECT (prevents fractures, muscle injuries)
• Contraindicated in: pseudocholinesterase deficiency, hyperkalemia (burns, crush injuries), history of malignant hyperthermia, denervation injuries
• Alternative: Rocuronium (non-depolarizing; reversed with sugammadex)

Oxygenation:

• 100% oxygen via bag-mask ventilation before and after stimulus
• Hyperventilation (5–10 deep breaths), lowers seizure threshold by inducing hypocapnia

1.6.3 Electrode Placement

d'Elia Placement (RUL): One electrode 3 cm above the midpoint of the right zygoma and orbital ridge (temporal); second electrode 3 cm to the right of the vertex.

Lancaster Position (Bilateral): Electrodes 3–4 cm above the midpoint of a line joining the external canthus and external auditory meatus, bilaterally.

1.6.4 Isolated Limb Technique (Motor Seizure Monitoring)

• A blood pressure cuff is inflated above systolic pressure on one forearm or ankle BEFORE succinylcholine injection
• Succinylcholine cannot reach that limb, muscles in the isolated limb contract during the seizure
• This allows direct visualization of motor seizure duration and generalization
• Minimum adequate motor seizure: 25 seconds

1.6.5 Stimulus Delivery and Seizure Adequacy

Electrical Parameters:

• Modern ECT machines deliver brief-pulse or ultra-brief pulse square-wave stimuli
• Key parameters:
• Frequency (Hz): Pulses per second
• Pulse width (ms): Duration of each pulse
• Duration (seconds): Length of stimulus train
• Current (amperes, A): Fixed in most machines (~0.8–0.9 A)
• Charge (millicoulombs, mC): Key dosing parameter = Current × Pulse width × Frequency × Duration

Brief-pulse vs Ultra-brief pulse:

Seizure Threshold Determination:

• Titration method: Start below estimated threshold; increase in steps until seizure achieved. Seizure threshold established on first session; subsequent sessions dosed relative to threshold (bilateral: 1.5–2x threshold; RUL: 6x threshold)
• Fixed-dose method: Use age-based formula (age/2 = approximate threshold in % for Mecta machines) or a fixed empirical dose
• Advantages of titration: more precise dosing, individualized; reduces cognitive risk
• Disadvantages: requires extra session (first session may be subtherapeutic)

Seizure Adequacy Criteria:

Signs of Inadequate Seizure:

• Short duration (<20 seconds EEG; <25 seconds motor)
• Failure to generalize (focal, not bilateral tonic-clonic)
• No postictal suppression on EEG
• Management: re-stimulate within same session (up to 3 attempts); increase stimulus energy; consider hyperventilation; consider switching anesthetic agent

Missed Seizure Management:

1. Wait 20 seconds, sometimes seizure is delayed
2. Hyperventilate patient (5 breaths)
3. Restimulate at higher energy (increment 25–50%)
4. Re-oxygenate fully before restimulation
5. If still no seizure after 3 attempts: abort session, review medications (benzodiazepines?), plan next session with different anesthesia

1.7 Course of ECT

1.7.1 Standard Acute Course

• Frequency: 3 sessions/week (Monday-Wednesday-Friday in most centers)
• Number of sessions: Typically 6–12 sessions for depression; 8–20 for schizophrenia
• Assessment: Patient reassessed after every 3–4 sessions
• Response criteria: ≥50% reduction in Hamilton Depression Rating Scale (HDRS) or Montgomery-Asberg scores
• Remission criteria: Score below threshold on rating scale + clinical confirmation
• Continuation: Once remission achieved, continue 2–6 more sessions to consolidate

1.7.2 Maintenance ECT (M-ECT)

• Indicated for: patients with high relapse rate, multiple prior episodes, inadequate response to pharmacotherapy alone, patient preference
• Schedule (tapering): weekly x 4 weeks → fortnightly x 4 → monthly (indefinitely in some cases)
• Combination with pharmacotherapy recommended
• Cognitive monitoring essential
• MHCA 2017 considerations: requires ongoing consent

1.8 Side Effects of ECT

1.8.1 Cognitive Side Effects (Most Clinically Significant)

Acute Confusional State (Post-ictal):

• Present immediately after each session
• Duration: 15–60 minutes typically
• Features: disorientation, confusion, agitation
• Management: reassurance, reorientation, quiet environment; rarely haloperidol 0.5–1 mg

Anterograde Amnesia:

• Inability to form new memories during ECT course
• Present during acute treatment course
• Usually resolves within weeks of completing ECT
• Less severe with RUL and ultra-brief pulse

Retrograde Amnesia:

• Loss of memories from the period surrounding ECT
• Most prominent for autobiographical events around the time of treatment
• Can extend months to years prior (especially with bilateral ECT)
• Personal memories more affected than semantic memories
• Partial recovery occurs over weeks to months; some permanent loss possible
• More severe with: bilateral placement, high-dose, sine-wave (not used now), many sessions

Objective Cognitive Testing:

• Executive function and processing speed may be transiently impaired
• Verbal memory most affected
• Visuospatial memory less affected
• Global cognitive function (MMSE) usually preserved

Strategies to Minimize Cognitive Side Effects:

1. Use RUL instead of bilateral placement where possible
2. Use ultra-brief pulse width
3. Use minimum effective stimulus dose
4. Space sessions (2x/week instead of 3x)
5. Use propofol or methohexital (but consider seizure threshold effects)
6. Monitor with serial cognitive testing (MMSE, Hopkins Verbal Learning Test)
7. Treat contributing factors (hypothyroidism, nutritional deficiencies)

1.8.2 Cardiovascular Effects

• Parasympathetic phase (0–10 seconds): Bradycardia, can cause asystole (prevented by anticholinergic premedication)
• Sympathetic phase (during/after seizure): Tachycardia, hypertension, can be marked
• Management: beta-blockers (esmolol, labetalol) for hypertension/tachycardia
• Nitrates for hypertensive emergency
• Post-ictal bradycardia may occur
• ECG changes: ST changes, PVCs (usually transient)

1.8.3 Other Side Effects

1.9 Modified vs Unmodified ECT

1.10 Consent for ECT Under MHCA 2017

1.10.1 Sections 94–95 of MHCA 2017

Section 94, Consent for ECT (Adults with Mental Illness):

• ECT must not be administered without informed consent from the patient
• Patient must have decision-making capacity (DMC) at the time of consent
• If patient lacks DMC: consent from nominated representative + opinion of a second psychiatrist
• If no nominated representative: seek consent from any relative as defined in the Act
• Emergency exception: ECT may be given in a life-threatening emergency after a second psychiatrist certifies it is necessary to prevent immediate risk to life
• Emergency ECT without consent: Permissible only when: (a) life is at immediate risk; (b) a second psychiatrist certifies; (c) documented fully
• After emergency: patient must be informed of what was done and why, as soon as they have capacity

Section 95, ECT for Minors (Under 18):

• ECT is prohibited for persons under 18 years of age under MHCA 2017
• No exception for emergencies in minors
• This is one of the few absolute prohibitions in the Act

1.10.2 Consent Process (Practical)

• Written informed consent (MHCA Form)
• Consent given after patient understands: what ECT is, why it is recommended, likely benefits and risks, alternatives, right to withdraw consent at any time
• Consent should be re-affirmed before each session (especially if patient's capacity has fluctuated)
• Advance Directive (Section 5–11, MHCA) may specify patient's wishes about ECT, must be honored
• Patient has the right to refuse ECT even if it is the best treatment

1.10.3 ECT in Pregnancy (Consent Considerations)

• Full informed consent from patient
• Obstetric consultation and consent
• Additional consent for fetal monitoring
• Risk-benefit discussion documented: ECT vs untreated severe illness vs pharmacotherapy risks

1.11 ECT in Special Populations

1.11.1 Pregnancy

• ECT is preferred over antidepressants/antipsychotics in first trimester for severe illness
• No teratogenic effects documented
• Risks of ECT in pregnancy:
• Premature labor (uterine contractions can occur)
• Fetal bradycardia (monitor fetal heart rate)
• Aortocaval compression in late pregnancy (left lateral decubitus)
• Aspiration risk (increased in pregnancy, use antacid premedication)
• Succinylcholine, plasma cholinesterase levels fall in pregnancy; prolonged apnea possible
• Protocol modifications for pregnancy:
• Obstetric anesthesiologist present
• Fetal heart rate monitoring (after 16 weeks)
• Tocolytic standby (ritodrine) for premature labor
• Antacid (sodium citrate) premedication
• Left lateral tilt of table
• Intubation if airway concerns
• Use low ECT dose (minimize fetal hypoxia during maternal hyperventilation)
• Uterine contraction monitoring

1.11.2 Elderly

• ECT generally safe and effective
• Cognitive side effects more pronounced, use RUL, ultra-brief pulse, 2x/week
• Delirium more common post-ECT, shorter sessions between treatments
• Higher anesthesia risk, careful workup
• Drug interactions more likely, extensive medication review
• Higher response rates than in younger patients (particularly for melancholic depression)
• Stimulus dosing: elderly have higher seizure threshold, may need more energy

1.11.3 Children and Adolescents

• Banned under MHCA 2017 (Section 95) for those under 18
• Despite evidence of efficacy in adolescents globally, Indian law prohibits it
• International perspective (APA, AACAP): ECT can be used in adolescents as a last resort for severe, treatment-resistant illness
• In India: examinees must know the legal prohibition

1.12 Brief-Pulse vs Ultra-Brief Pulse (Detailed)

SECTION 2: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS)

2.1 Mechanism of Action

• A rapidly alternating magnetic field is generated by a coil placed over the scalp
• This induces electrical currents in the underlying cortex (Faraday's law of electromagnetic induction)
• Depending on frequency: high-frequency (≥10 Hz) stimulation is excitatory; low-frequency (≤1 Hz) is inhibitory
• Non-invasive: no anesthesia, no seizure, no cognitive side effects
• Does not penetrate deeper than 2–3 cm from skull surface

2.2 Standard rTMS Parameters for Depression

Deep TMS (dTMS):

• Uses H-coil (Brainsway) to reach deeper structures
• FDA-approved for OCD and smoking cessation in addition to depression

2.3 Indications for rTMS

• Treatment-resistant major depression (failed 1–4 antidepressant trials), FDA approved 2008, NICE approved
• OCD (deep TMS with H7 coil), FDA approved 2018
• PTSD, emerging evidence
• Chronic pain, motor cortex stimulation
• Schizophrenia, low-frequency left temporal TMS for auditory hallucinations
• Bipolar depression, limited evidence; some guidelines support

2.4 Theta Burst Stimulation (TBS)

• A patterned protocol: bursts of 3 pulses at 50 Hz, repeated at 5 Hz
• Intermittent TBS (iTBS): Excitatory, equivalent efficacy to 10 Hz rTMS in 3 minutes (vs 37 minutes)
• Continuous TBS (cTBS): Inhibitory
• iTBS is FDA-approved and now widely used, much faster protocol
• Response rates comparable to standard 10 Hz rTMS

2.5 Contraindications to rTMS

• Metallic implants in or near head (cochlear implants, deep brain stimulators, metal plates in skull)
• Seizure disorder (relative, can induce seizure)
• Pregnancy (limited data, generally avoided)
• Cardiac pacemaker (not a problem unless in head/neck region)

2.6 Side Effects of rTMS

• Headache (most common), usually mild
• Scalp discomfort/pain at coil site
• Facial muscle twitching during stimulation
• Seizure induction, rare (<0.1%); more risk with high-intensity protocols
• No cognitive effects (a key advantage over ECT)
• No systemic effects (no anesthesia)

SECTION 3: OTHER BRAIN STIMULATION THERAPIES

3.1 Vagus Nerve Stimulation (VNS)

3.2 Deep Brain Stimulation (DBS)

3.3 Transcranial Direct Current Stimulation (tDCS)

3.4 Magnetic Seizure Therapy (MST)

• Uses transcranial magnetic stimulation delivered at high intensity to induce a seizure
• Requires anesthesia (like ECT)
• More focal stimulation than ECT, potentially less cognitive side effects
• Still investigational; limited availability

SECTION 4: POSTPARTUM PSYCHIATRIC DISORDERS

4.1 Overview and Classification

The postpartum period (up to 1 year after delivery) is a time of high psychiatric vulnerability. Three main syndromes are recognized, distinguished by timeline, severity, and need for intervention:

4.2 Baby Blues (Maternity Blues)

Epidemiology: 50–70% of all postpartum women; universal phenomenon across cultures

Onset: Day 1–5 post-delivery (peaks day 3–5)

Duration: Self-limited; resolves by day 14 by definition

Clinical Features:

• Emotional lability (crying without clear reason)
• Irritability
• Anxiety
• Sleep disturbance (beyond that caused by infant care)
• Mild confusion
• Rapid mood swings

Pathophysiology:

• Rapid fall in estrogen and progesterone post-delivery
• Estrogen withdrawal affects serotonergic and dopaminergic systems
• Sleep deprivation
• Psychosocial adjustment demands

Management:

• Supportive counseling
• Psychoeducation (normalize the experience)
• Adequate sleep and social support
• Monitor, if symptoms persist beyond 2 weeks, reassess for PPD

4.3 Postpartum Depression (PPD)

4.3.1 Definition

• DSM-5: A major depressive episode with "peripartum onset", onset during pregnancy or within 4 weeks postpartum (clinical practice extends this to 12 weeks, sometimes up to 1 year)
• Edinburgh Postnatal Depression Scale (EPDS) is the standard screening tool

4.3.2 Epidemiology

• Prevalence: 10–15% (developed world); 20–25% in low-middle income countries
• Higher rates in: first-time mothers, teenagers, low socioeconomic status, prior psychiatric history
• Paternal PPD also occurs (~10% of fathers within first year)

4.3.3 Risk Factors (HIGH YIELD)

4.3.4 Clinical Features

• Persistent low mood, tearfulness
• Anhedonia
• Sleep disturbance (beyond infant demands)
• Appetite changes
• Excessive guilt and self-criticism ("I'm a bad mother")
• Impaired concentration and decision-making
• Poor mother-infant bonding
• Intrusive thoughts about harming infant (ego-dystonic, OCD-type thoughts, distinguished from psychosis)
• Suicidal ideation

4.3.5 Edinburgh Postnatal Depression Scale (EPDS)

EPDS Domains: Anhedonia (1 item), anxiety (3 items), low mood (2 items), self-harm (1 item), guilt/coping (3 items)

4.3.6 Pharmacotherapy for PPD

General Principles:

• Drug choice depends on breastfeeding status (majority of mothers breastfeed)
• Hale's Lactation Risk Categories (LRC):
• L1 = Safest (compatible with nursing)
• L2 = Safer
• L3 = Moderately safe
• L4 = Possibly hazardous
• L5 = Contraindicated

Non-pharmacological treatment:

• Interpersonal therapy (IPT), specifically adapted for PPD; first-line for mild-moderate PPD
• Cognitive-behavioral therapy (CBT)
• Mother-infant therapy
• Social support intervention
• Brexanolone (Zulresso), IV neuroactive steroid; FDA approved 2019 for moderate-severe PPD; single 60-hour IV infusion; works via GABAergic mechanism (synthetic allopregnanolone); not available in India

4.4 Postpartum Psychosis (PPP)

4.4.1 Definition and Epidemiology

• Most severe postpartum psychiatric emergency
• Prevalence: 1–2 per 1,000 deliveries
• Higher risk in women with bipolar disorder (risk: 25–50% with each delivery)
• Also higher in women with prior PPP, family history of bipolar or PPP

4.4.2 Onset and Course

• Onset: Typically within first 2 weeks post-delivery (often within 48–72 hours)
• Rapid onset distinguishes it from PPD
• Course: fluctuating, may oscillate between elation, depression, confusion within hours/days
• High risk of recurrence with subsequent pregnancies

4.4.3 Clinical Features

• Confusion and disorientation, often the first sign; disproportionate to the clinical picture
• Rapid mood fluctuations, may swing from elation to despair within hours
• Visual, auditory, olfactory hallucinations
• Delusions, often related to the infant (infant is special/cursed/possessed/not hers)
• Thought disorganization
• Psychomotor disturbance, may be agitated or retarded
• Sleep disturbance, often severe insomnia despite exhaustion
• Impaired insight

4.4.4 Differential Diagnosis

• Postpartum delirium (sepsis, eclampsia, electrolyte disturbance, thyroiditis, Sheehan's syndrome)
• First-episode schizophrenia
• Brief psychotic disorder
• Bipolar disorder with psychotic features (PPP is often the first presentation of bipolar disorder)
• Substance intoxication/withdrawal

Organic causes to exclude in PPP:

• Sepsis (puerperal sepsis)
• Eclampsia
• Thyroid storm / autoimmune thyroiditis
• Electrolyte disturbances (Na+, Mg2+)
• Cortical vein thrombosis
• Sheehan's syndrome (pituitary infarction)
• Wernicke's encephalopathy (thiamine deficiency)

4.4.5 Management of PPP

Immediate:

1. Psychiatric admission (mother-baby unit if available; protects mother-infant bond)
2. Full physical examination and investigations to exclude organic causes
3. Risk assessment for infanticide and suicide
4. Ensure infant safety, supervision of all mother-infant contact initially

Pharmacological:

• Antipsychotics, olanzapine (first choice), haloperidol (if sedation needed rapidly)
• Olanzapine 5–10 mg/day; adjust as needed
• If breastfeeding: olanzapine or quetiapine preferred (low milk transfer)
• Mood stabilizer (if bipolar features clear):
• Lithium, effective; can be used with monitoring; some transfer to breast milk, check infant lithium levels
• Valproate, effective but teratogenic for future pregnancies; causes hepatotoxicity concerns; generally avoided in breastfeeding (transfer is low but infant liver immature)
• Benzodiazepines, for acute agitation and sleep restoration (lorazepam 1–2 mg; use short-term)
• ECT, considered early for severe cases, catatonic features, or life-threatening illness

Psychosocial:

• Maintain mother-infant relationship with supervision
• Family psychoeducation
• IPT adapted for postpartum period
• Plan for relapse prevention for subsequent pregnancies

4.4.6 Infanticide Risk Assessment

Risk Factors for Infanticide:

• Active psychosis with delusions about the infant
• Command hallucinations ordering harm to infant
• Altruistic infanticide ideation ("the child will suffer in this world")
• Suicidal ideation with plan to kill infant first
• Lack of protective factors (social support, religious prohibition)
• History of abuse or trauma

Assessment:

• Direct inquiry about thoughts of harming infant (does not increase risk)
• Assessment of command hallucinations
• Assessment of relationship with infant
• Assessment of support network

4.5 Breastfeeding and Psychotropics

4.6 Teratogenicity of Psychotropics

4.6.1 High-Risk Drugs (Avoid in Pregnancy)

4.6.2 Relatively Safer Options in Pregnancy

• Depression: Sertraline (most data); second-line escitalopram, citalopram
• Bipolar disorder: Lamotrigine (risk of cleft palate ~0.2–0.9%, lower than valproate); quetiapine; if lithium required, use with fetal echo
• Psychosis: Haloperidol (most data), olanzapine (watch gestational diabetes)
• Anxiety: Psychotherapy first; if drugs needed, sertraline or low-dose lorazepam short-term

4.7 Premenstrual Dysphoric Disorder (PMDD)

DSM-5 Criteria:

• 5+ symptoms in final week before menses, improving within few days of onset, minimal/absent in postmenstrual week
• Core symptoms: affective lability, irritability/anger, depressed mood, anxiety/tension
• Additional: anhedonia, difficulty concentrating, fatigue, appetite changes, hypersomnia/insomnia, feeling overwhelmed, physical symptoms (breast tenderness, bloating, weight gain)
• Causes marked distress or functional impairment
• Symptoms documented prospectively for 2 menstrual cycles (DRSP, Daily Record of Severity of Problems)
• Not attributable to another disorder

Prevalence: 3–8% of women of reproductive age

Pathophysiology:

• Abnormal CNS sensitivity to normal cyclical fluctuations in estrogen and progesterone
• Particularly to allopregnanolone (progesterone metabolite), a GABA-A receptor positive allosteric modulator
• Serotonergic dysregulation
• Not a hormone "deficiency", hormone levels are normal

Treatment:

• First-line: SSRIs, sertraline, fluoxetine (Sarafem), escitalopram
• Can be given continuously or only in luteal phase (day 14 to menses), luteal phase dosing effective and reduces side effects
• Second-line: Continuous OCP (suppresses ovulation cycle); GnRH agonists (leuprolide)
• Third-line: Ovarian suppression (GnRH + add-back therapy), bilateral oophorectomy (last resort)
• Non-pharmacological: CBTI, exercise, calcium supplementation (1200 mg/day, modest evidence)

SECTION 5: TELEPSYCHIATRY

5.1 Definition and Models

Telepsychiatry: The delivery of psychiatric services using telecommunication technologies, including synchronous video conferencing, asynchronous store-and-forward, telephone, and text-based modalities.

Models:

• Synchronous: Real-time video or telephone consultation between clinician and patient
• Asynchronous (Store-and-Forward): Recorded data (video, images, notes) sent to a specialist for review, used in dermatology, radiology; limited use in psychiatry
• Hybrid: Combination of in-person and telehealth
• Hub-and-Spoke: Specialist at hub (tertiary center) consults with clinician at spoke (peripheral/primary care)
• Direct-to-patient: Patient connects directly with psychiatrist from home
• E-mental health: Self-guided apps, online CBT programs, chatbot interventions

5.2 Telemedicine Practice Guidelines 2020 (India)

Authority: Ministry of Health and Family Welfare (MoHFW), Government of India

Key Provisions:

5.3 MHCA 2017 and Telepsychiatry

• MHCA 2017 does not specifically address telepsychiatry by name
• The Act mandates access to mental health care without discrimination based on location
• Telemedicine is viewed as a mechanism to fulfill this mandate, particularly for rural access
• Practitioners practicing telepsychiatry must comply with both MHCA 2017 and the Telemedicine Practice Guidelines 2020
• Documentation requirements under MHCA (including consent, medical records) apply equally to telepsychiatry

5.4 Evidence Base for Telepsychiatry

5.5 Platforms and Technology

• Video platforms: Secure, HIPAA/DISHA-compliant platforms preferred; WhatsApp and standard video calls technically permitted under Indian guidelines but with limitations
• DISHA (Digital Information Security in Healthcare Act): Proposed legislation for health data protection (not yet enacted as of 2025)
• PG exams telepsychiatry model: Hub (PG exams, Bengaluru) + spoke (district hospitals) model; well-validated; services to rural Karnataka; trained ASHA workers and PHC doctors as the "first contact"

5.6 Limitations of Telepsychiatry

5.7 Tele-Assessment Challenges

• Mental Status Examination via screen: Appearance, behavior, speech, affect assessable; thought process and content assessable; cognition (MMSE) partially assessable
• Cannot assess: Gait, tremors, rigidity (for EPS monitoring), physical signs of self-harm, nutritional status fully
• Rating scales: HAM-D, MADRS, PANSS can be administered by video
• Neuropsychological testing: Requires standardized conditions; most not validated for remote administration

SECTION 6: COMMUNITY PSYCHIATRY IN INDIA

6.1 National Mental Health Programme (NMHP)

Launched: 1982 (revised 2003, 2017)

Objectives:

1. Prevention and treatment of mental and neurological disorders
2. Rehabilitation of the mentally ill
3. Reduction of associated disability

Components:

1. District Mental Health Programme (DMHP), primary implementation unit
2. Medical College Resource Centres (MCRC)
3. Centres of Excellence (CoE), PG exams, LGB Regional Institute
4. Special centres for epilepsy, rehabilitation
5. Human resource development (HRD)
6. IEC (Information, Education, Communication)
7. NGO participation

6.2 District Mental Health Programme (DMHP)

Launched: 1996, Bellary, Karnataka (pilot)

Coverage: All districts of India under 12th Five Year Plan

Target population: All mental illness, with focus on severe mental illness and suicide

Structure of DMHP at District Level:

Services under DMHP:

• Outpatient treatment at district hospitals
• School mental health program
• College mental health program
• Workplace mental health
• Suicide prevention
• Training of general health workers
• Community awareness camps

Manpower under DMHP (per district):

• 1 Psychiatrist
• 1 Clinical Psychologist
• 1 Psychiatric Social Worker
• 1 Psychiatric Nurse
• Case Registry Officer
• Data entry operators

6.3 Other National Programs Relevant to Psychiatry

SECTION 7: CULTURAL PSYCHIATRY

7.1 Culture-Bound Syndromes (India-Specific)

DSM-5 approach: Culture-bound syndromes replaced by "Cultural Concepts of Distress", three types:

1. Cultural syndromes (distinct patterns of symptoms in specific cultures)
2. Cultural idioms of distress (ways of expressing distress, e.g., "heart pain," "liver distress")
3. Cultural explanations (causal attributions, supernatural, spiritual, humoral)

7.2 Stigma and Mental Health

Internalized stigma: Individual absorbs negative societal attitudes about mental illness into self-concept; leads to shame, concealment, treatment avoidance

Structural stigma: Institutional policies and resource allocation that disadvantage people with mental illness

Social stigma: Public attitudes and behaviors toward people with mental illness

Anti-stigma interventions:

• Contact-based education (most effective)
• Protest campaigns
• Education-based approaches
• Mental health literacy programs
• Media guidelines for reporting on mental health/suicide

Mental Health Act and Stigma: MHCA 2017 addresses stigma by emphasizing rights, dignity, non-discrimination, and participation of persons with mental illness in decisions about their care.

SECTION 8: PSYCHIATRIC EMERGENCIES OVERVIEW

8.1 Common Psychiatric Emergencies

8.2 MHCA 2017 and Psychiatric Emergencies

• Emergency admission (Section 89): Person may be admitted for up to 24 hours without formal procedure in a genuine psychiatric emergency
• Must be formally assessed within 24 hours
• Rights (legal aid, nominated representative contact, right to be heard) apply even in emergency
• Restraint and seclusion must be humane, minimal, and documented

KEY REFERENCES

1. Kaplan & Sadock's Synopsis of Psychiatry, 12th Edition (Sadock, Sadock, Ruiz)
2. APA Task Force on Electroconvulsive Therapy, 3rd Edition (2001), updated practice parameters 2022
3. Stahl's Essential Psychopharmacology, 5th Edition (Stahl)
4. The Mental Health Care Act, 2017 (India), Gazette of India
5. Telemedicine Practice Guidelines 2020, MoHFW, Government of India
6. PG exams Standards for ECT Practice in India
7. Hale's Medications and Mothers' Milk, 19th Edition (Hale, Krutsch)
8. Edinburgh Postnatal Depression Scale, Cox, Holden & Sagovsky (1987), Br J Psychiatry
9. National Mental Health Policy of India 2014
10. WHO Mental Health Action Plan 2013–2030

Model Answers

Sources: Kaplan & Sadock 12th ed., APA ECT Task Force 3rd ed., MHCA 2017, Stahl's 5th ed., Telemedicine Practice Guidelines 2020

ANSWER 1

Describe the indications and technique of ECT. [10 marks]

Indications for ECT

Primary / First-Line Indications (where speed or safety justifies ECT before drug trials):

1. Severe major depressive episode with psychotic features, response rate 85–90%; psychotic depression responds less well to antidepressants alone
2. Suicidal emergency, ECT produces antidepressant and antisuicidal effects within days; cannot wait 4–6 weeks for drug response
3. Catatonia unresponsive to benzodiazepines, ECT is the definitive treatment; lorazepam trial should precede ECT in most cases
4. Acute mania (severe, treatment-resistant), when lithium/antipsychotics are insufficient or dangerous (renal failure, pregnancy)
5. Neuroleptic Malignant Syndrome (NMS), after acute medical stabilization; addresses the underlying dopaminergic dysregulation
6. Malignant catatonia, overlap with NMS; ECT urgently indicated
7. Severe depression with refusal to eat/drink, medical compromise; ECT faster than drugs

Secondary Indications (after ≥2 failed adequate pharmacotherapy trials):

• Treatment-resistant depression (TRD)
• Treatment-resistant bipolar disorder
• Schizophrenia with prominent affective/catatonic features
• Schizoaffective disorder

Special Populations:

• Pregnancy, preferred over most psychotropics in first trimester for severe illness
• Elderly, safe; high response rates; monitor cognition
• Parkinson's disease, improves both mood and motor fluctuations

Technique of ECT

1. Pre-ECT Workup:

• Full psychiatric evaluation confirming indication
• Informed consent per MHCA 2017 (Sections 94–95)
• Investigations: CBC, electrolytes, renal function, blood glucose, ECG, chest X-ray, spine X-ray (elderly)
• Cognitive baseline (MMSE)
• Drug review: withhold/reduce benzodiazepines, lithium, anticonvulsants, theophylline; withhold MAOIs 2 weeks
• Anesthesia evaluation

2. Pre-procedure:

• NPO: 6–8 hours for solids, 4 hours for clear liquids
• IV access
• Monitoring: ECG, pulse oximetry, blood pressure, EEG
• Anticholinergic premedication: glycopyrrolate 0.2 mg IV (prevents bradycardia and secretions)
• EEG electrodes applied bilaterally

3. Anaesthesia:

• Induction agent: Thiopentone sodium 2–4 mg/kg IV (gold standard in India); Propofol 1–2 mg/kg (raises seizure threshold, need higher ECT dose)
• Muscle relaxant: Succinylcholine 0.5–1.5 mg/kg IV (depolarizing; onset 30–60 sec; prevents fractures)
• Oxygenation: 100% O2 via bag-mask; hyperventilate (5–10 breaths, lowers seizure threshold by reducing CO2)

4. Electrode Placement:

• Bilateral (bitemporal): Highest efficacy; maximum cognitive side effects
• Right Unilateral (RUL): Less cognitive effects; requires 6x seizure threshold to match bilateral efficacy
• Bifrontal: Intermediate

5. Isolated Limb Technique:

• Blood pressure cuff inflated on one forearm/ankle above systolic pressure before succinylcholine
• Allows direct visualization of motor seizure in isolated limb
• Adequate motor seizure: ≥25 seconds

6. Stimulus Delivery:

• Brief-pulse or ultra-brief pulse square-wave stimulus
• Key parameters: frequency (Hz), pulse width (ms), duration (s), current (A), expressed as charge in millicoulombs (mC)
• Dosing: titration method (precise, preferred) or fixed-dose (age-based estimate)
• Bilateral ECT: 1.5–2x seizure threshold; RUL: 6x seizure threshold

7. Seizure Adequacy:

• Motor: ≥25 seconds (isolated limb)
• EEG: ≥20–25 seconds with postictal suppression
• If inadequate: re-stimulate (up to 3 attempts); increase energy 25–50%; hyperventilate

8. Course:

• Standard: 3 sessions/week (Mon-Wed-Fri); 6–12 sessions for depression
• Assess after every 3–4 sessions
• Maintenance ECT: tapering schedule for relapse prevention

ANSWER 2

Consent for ECT under the Mental Health Care Act, 2017. [5 marks]

Legal Framework (MHCA 2017)

Section 94, ECT in Adults:

1. Informed consent is mandatory before ECT can be administered to any adult
2. Patient must have decision-making capacity (DMC) at the time of consent
3. The patient must understand:
4. What ECT is and how it is administered
5. Why it is recommended
6. Expected benefits and risks (including cognitive side effects)
7. Available alternatives
8. Right to refuse or withdraw consent at any time
9. If patient lacks DMC:
10. Consent from Nominated Representative (NR) + second psychiatrist's opinion
11. If no NR: consent from any relative as defined in the Act + second psychiatrist
12. Emergency exception:
13. ECT may be given without consent only if life is at immediate risk
14. A second psychiatrist must certify the emergency necessity
15. Full documentation is mandatory
16. Patient must be informed of what was done as soon as DMC is restored
17. Advance Directive (Sections 5–11 MHCA): If a patient has previously specified wishes about ECT in a valid Advance Directive, those must be honored

Section 95, ECT in Minors:

• ECT is completely prohibited for all persons under 18 years of age
• There are no exceptions, not even in life-threatening emergencies
• This is an absolute prohibition

Practical Points:

• Consent must be in writing, using designated MHCA forms
• Consent should be reaffirmed before each session if the patient's capacity has fluctuated
• Patients have the right to refuse ECT even when it is the clinically optimal choice
• Forced ECT (except the narrow emergency provision with second opinion) violates the Act

ANSWER 3

Bilateral versus right unilateral ECT: Compare and contrast. [5 marks]

Swipe to compare →

ANSWER 4

ECT in pregnancy: Indications, modifications, and risks. [5 marks]

Indications for ECT in Pregnancy

ECT is considered the preferred treatment (over most psychotropics) in the following scenarios during pregnancy:

• Severe major depressive episode in first trimester (when teratogenic risk of drugs is highest)
• Acute psychosis or mania in pregnancy requiring rapid control
• Treatment-resistant depression or psychosis in any trimester
• Suicidal emergency in pregnancy
• Severe catatonia in pregnancy
• When rapid response is critical and pharmacotherapy poses unacceptable fetal risk (e.g., valproate for bipolar disorder)

Modifications to ECT Protocol in Pregnancy

Risks of ECT in Pregnancy

ANSWER 5

Postpartum psychosis: Clinical features, differential diagnosis, and management. [10 marks]

Definition

Postpartum psychosis (PPP) is a severe psychiatric emergency occurring in 1–2 per 1,000 deliveries, typically within the first 2 weeks post-delivery. It is characterized by the rapid onset of psychosis, mood disturbance, and confusion in the postpartum period.

Clinical Features

Onset: Within 2 weeks of delivery (typically days 1–14; peak days 3–10)

Characteristic Features:

1. Confusion and disorientation, often the earliest sign; disproportionate to the clinical picture; distinguishes PPP from other psychoses
2. Rapid mood fluctuations, oscillations between elation, depression, and dysphoria within hours or days
3. Perceptual disturbances, visual, auditory, olfactory hallucinations
4. Delusions, often related to infant (special powers, cursed, not her child, the child must be harmed "to save" it)
5. Thought disorganization, incoherence, flight of ideas, tangentiality
6. Severe insomnia, disproportionate to infant care demands
7. Psychomotor disturbance, agitation or stupor
8. Impaired insight
9. Command hallucinations (in severe cases), risk factor for infanticide

Differential Diagnosis

Organic Causes to Exclude:

• Puerperal sepsis (fever, elevated WBC, source)
• Eclampsia (BP, proteinuria, seizures)
• Thyroid storm / autoimmune thyroiditis (TSH, free T4)
• Electrolyte disturbances (Na+, Mg2+, Ca2+)
• Cortical vein thrombosis (headache, neurological signs, MRI)
• Sheehan's syndrome (pituitary infarction post-PPH; cortisol low)
• Wernicke's encephalopathy (thiamine deficiency; ataxia, ophthalmoplegia, confusion)

Management

1. Assessment and Immediate Safety:

• Urgent psychiatric assessment; risk assessment for infanticide and suicide
• Direct questioning about thoughts of harming infant (safe and necessary)
• Assess command hallucinations and delusions about infant
• Ensure supervised contact with infant until risk assessment complete

2. Admission:

• Inpatient psychiatric admission mandatory
• Mother-baby unit (if available), preserves mother-infant bond while ensuring safety
• If unavailable: general psychiatric ward with supervised infant contact

3. Organic workup:

• Full blood count, metabolic panel (electrolytes, glucose, renal, liver, calcium)
• Thyroid function (TSH, free T4, thyroid antibodies)
• Blood cultures if fever present
• Neuroimaging (CT/MRI) if neurological signs present
• Urine toxicology

4. Pharmacological Management:

5. Breastfeeding Considerations:

• Olanzapine, haloperidol: low milk transfer, acceptable
• Lithium: monitor infant serum lithium levels; some prefer bottle-feeding
• Valproate: low milk transfer; generally acceptable
• Decision shared with mother; untreated illness also harms infant

6. Long-term Planning:

• Lithium for prophylaxis in subsequent pregnancies (start immediately post-delivery)
• Recurrence risk with subsequent deliveries: 25–50% without prophylaxis; reduced with lithium
• Psychoeducation for patient and family
• Mental health monitoring plan for future pregnancies

ANSWER 6

Screening for postpartum depression: The Edinburgh Postnatal Depression Scale. [5 marks]

Background

The Edinburgh Postnatal Depression Scale (EPDS) is the most widely used and validated screening tool for postpartum depression (and antenatal depression). It was developed by Cox, Holden, and Sagovsky (1987) and published in the British Journal of Psychiatry.

Structure

Domains Covered

1. Ability to laugh / see funny side of things (anhedonia)
2. Looking forward with enjoyment (anhedonia)
3. Blaming self unnecessarily (guilt)
4. Anxiety and worry
5. Fear/panic without good reason
6. Things overwhelming / inability to cope
7. Unhappiness, difficulty sleeping (beyond infant waking)
8. Feeling sad or miserable
9. Unhappiness, crying
10. Thoughts of self-harm or suicide, Item 10 requires immediate clinical assessment regardless of total score

Cutoff Scores

Note: Some guidelines use ≥10 as the cutoff; others ≥12 or ≥13. NICE guidelines use ≥10; Edinburgh Health Board (original) used ≥13.

Timing of Administration

• Antenatally: 28–32 weeks (antenatal depression predicts PPD)
• Postnatally: 4–6 weeks; repeat at 3 months
• Can be used for ongoing monitoring throughout postnatal period

Limitations

• Screening tool only, not a diagnostic instrument
• Does not capture psychotic features
• May miss anxious presentations (weighted toward low mood)
• Cross-cultural validity variable (requires local validation)
• Paternal version available (Edinburgh Paternal Depression Scale, EPDS-P)

ANSWER 7

Drugs safe for use in breastfeeding in psychiatry. [5 marks]

Principles of Psychotropic Safety in Breastfeeding

Hale's Lactation Risk Categories (LRC):

• L1 = Safest (no risk observed in extensive studies)
• L2 = Safer (limited adverse effects; probably compatible)
• L3 = Moderately safe (moderate risk; use only if benefit > risk)
• L4 = Possibly hazardous (significant risk)
• L5 = Contraindicated

Key pharmacokinetic factors affecting infant exposure:

• Milk-to-plasma ratio (M/P ratio), lower = safer
• Molecular weight, higher molecular weight drugs transfer less
• Protein binding, highly protein-bound drugs transfer less
• Infant's hepatic maturity, younger infants metabolize drugs less efficiently
• Oral bioavailability, some drugs have poor infant absorption

Antidepressants

Antipsychotics

Mood Stabilizers

Benzodiazepines

ANSWER 8

rTMS: Mechanism, indications, and parameters. [5 marks]

Mechanism of Action

Repetitive Transcranial Magnetic Stimulation (rTMS) delivers rapidly alternating magnetic field pulses via a coil placed over the scalp. By Faraday's law of electromagnetic induction, this generates electrical currents in the underlying cortical neurons without requiring electrodes or anesthesia.

Frequency-dependent effects:

• High-frequency (≥10 Hz): Excitatory, increases cortical excitability and neuronal firing
• Low-frequency (≤1 Hz): Inhibitory, decreases cortical excitability

Mechanism in depression:

• Left DLPFC is hypoactive in depression
• High-frequency rTMS over left DLPFC restores activity → normalizes fronto-limbic circuitry
• Downstream effects: increased BDNF, normalized monoamine neurotransmission, modulation of default mode network

FDA-Approved Indications

1. Treatment-resistant major depression (2008), failed 1+ antidepressant trials
2. OCD, deep TMS (H7 coil) (2018)
3. Smoking cessation, deep TMS (2020)
4. MDD with anxious depression (2021)

Parameters for Depression

Theta Burst Stimulation (TBS)

• Pattern: 3 pulses at 50 Hz repeated at 5 Hz
• Intermittent TBS (iTBS): Excitatory, 600 pulses in 3 minutes; FDA-approved; non-inferior to standard 10 Hz
• Continuous TBS (cTBS): Inhibitory
• Major advantage: drastically shorter treatment time (3 min vs 37 min)

Advantages Over ECT

• No anesthesia required
• No cognitive side effects
• Outpatient procedure
• No seizure induction
• Can be used in medically frail patients

Disadvantages vs ECT

• Slower response (4–6 weeks vs days)
• Lower efficacy in severe illness
• Not effective in psychotic or catatonic states
• Infrastructure and cost

ANSWER 9

Telepsychiatry in India: Framework, evidence, and limitations. [5 marks]

Definition

Telepsychiatry refers to the delivery of psychiatric assessment, diagnosis, treatment, and monitoring using telecommunication technologies, primarily synchronous video consultations.

Legal Framework in India

Telemedicine Practice Guidelines 2020 (MoHFW):

• Issued by Ministry of Health and Family Welfare as Appendix 5 to IMC Amendment
• Only NMC/MCI-registered practitioners can practice telemedicine
• Most psychotropics (Schedule H/H1) can be prescribed via telemedicine
• Schedule X drugs (benzodiazepines, opioids, stimulants) CANNOT be prescribed via telemedicine
• Documentation standards equivalent to in-person practice
• Patient consent required
• First consultation for a new patient: in-person preferred; telemedicine for follow-up encouraged

MHCA 2017:

• Does not specifically name telepsychiatry
• Mandates equitable access to mental health care regardless of location
• Telepsychiatry is a mechanism to fulfill this mandate for underserved populations
• All MHCA provisions (consent, records, rights) apply equally

Evidence Base

• Depression: Multiple RCTs showing non-inferiority to in-person therapy (particularly CBT delivery)
• Anxiety disorders: Strong evidence; telehealth CBT for panic disorder, social anxiety, GAD
• PTSD: VA studies showing non-inferiority for Prolonged Exposure delivered by video
• Schizophrenia (stable): Effective for medication management and monitoring
• Meta-analyses: telepsychiatry non-inferior to in-person for most clinical outcomes (therapeutic alliance, symptom reduction, patient satisfaction)

PG exams Model (India)

• Hub-and-spoke model: PG exams (Bengaluru) as hub; district hospitals and PHCs as spokes
• Trained ASHA workers and PHC doctors as first point of contact
• Specialist consultation via video for complex cases
• Validated in rural Karnataka; adopted as national model reference

Limitations

ANSWER 10

District Mental Health Programme (DMHP): Structure and components. [5 marks]

Background

The DMHP was launched in 1996 at Bellary, Karnataka, as a pilot under the National Mental Health Programme (NMHP). It aimed to decentralize mental health services to the district level, moving away from the tertiary-care-only model.

Objectives

1. Provide mental health services at the district level
2. Train primary health care workers to identify and manage common mental disorders
3. Reduce burden on tertiary centers
4. Improve community awareness and reduce stigma
5. Facilitate rehabilitation and reintegration

Core Team at District Level (Per District)

Services Provided Under DMHP

1. Outpatient services at district hospital, diagnosis, treatment, follow-up
2. Inpatient services, acute management at district hospital
3. School mental health program, identify and support students with mental health issues; teacher training
4. College mental health program, counseling services at degree colleges
5. Workplace mental health, stress management programs
6. Training of primary health workers, PHC doctors, ANMs, ASHAs in mental health first aid
7. IEC activities, awareness camps, media campaigns
8. Suicide prevention, gatekeeper training, crisis intervention
9. Drug supply management, ensure availability of essential psychotropics at district level

NMHP vs DMHP (See also Comparisons Chapter)

• NMHP = National policy framework (launched 1982)
• DMHP = Operational implementation unit (launched 1996), the ground-level expression of NMHP

ANSWER 11

Maintenance ECT: Indications, schedule, and evidence. [5 marks]

Definition

Maintenance ECT (M-ECT) refers to the continued administration of ECT after the completion of a successful acute course, at gradually increasing intervals, to prevent relapse.

Indications

1. High frequency of relapse on pharmacotherapy alone
2. Multiple prior depressive or manic episodes
3. Treatment-resistant illness (inadequate response to pharmacotherapy)
4. Patient preference (especially if prior ECT response was superior to drug response)
5. Intolerance or contraindication to maintenance pharmacotherapy
6. High suicidal risk requiring ongoing aggressive management
7. Conditions where pharmacotherapy is not possible (certain medical comorbidities, pregnancy)

Schedule

The tapering schedule most commonly used:

• Weeks 1–4: Once weekly
• Weeks 5–8: Fortnightly
• Month 3 onwards: Monthly (ongoing if needed)
• Some protocols: individualize based on relapse risk, more frequent in high-risk patients

Combination with Pharmacotherapy

• Pharmacotherapy should be combined with M-ECT in most cases
• Combination of M-ECT + nortriptyline shown superior to nortriptyline alone in preventing relapse (Kellner et al., RCT)
• Lithium often combined with M-ECT in bipolar disorder

Cognitive Monitoring During M-ECT

• Serial cognitive testing every 3–6 months minimum
• MMSE, Hopkins Verbal Learning Test, or equivalent
• If significant cognitive decline: consider spacing sessions further; switch to RUL; use ultra-brief pulse
• Cognitive effects of M-ECT are cumulative but often manageable with placement and pulse-width optimization

Evidence

• Kellner et al. (2006) NEJM: M-ECT combined with nortriptyline superior to nortriptyline alone in preventing relapse after acute ECT
• Multiple observational studies: M-ECT effective for up to several years
• APA Task Force: M-ECT is an established, evidence-based intervention, not experimental

ANSWER 12

Cognitive side effects of ECT: Types, mechanisms, and management. [5 marks]

Types of Cognitive Effects

1. Post-ictal Confusional State:

• Onset: Immediately after each session
• Duration: 15–60 minutes (occasionally longer in elderly or high-dose bilateral ECT)
• Features: disorientation, agitation, confusion
• Self-limiting; requires reassurance and monitoring

2. Anterograde Amnesia:

• Inability to form new memories during the ECT treatment course
• Present during acute treatment; resolves within weeks of completing ECT
• Largely reversible

3. Retrograde Amnesia:

• Loss of memories from the period surrounding ECT
• Can extend months to years prior to treatment (especially with bilateral ECT)
• Autobiographical memory more affected than semantic memory
• Personal memories (dates, events, faces) more vulnerable than general knowledge
• Partial recovery over weeks to months; some permanent loss possible
• More severe with: bilateral placement, sine-wave (obsolete), high stimulus dose, frequent sessions

4. Working Memory and Executive Function:

• Transient impairment during acute ECT course
• Generally resolves after completion

5. Subjective Memory Complaints:

• Patients often report significant subjective memory impairment even when objective tests are normal
• Validate and explain; do not dismiss
• Some persistent subjective complaints may reflect permanent retrograde amnesia for personal memories

Mechanism

• Seizure-induced disruption of hippocampal memory consolidation processes
• Postictal suppression of hippocampal function
• Bilateral stimulation affects both hippocampi simultaneously → greater impact
• Right (non-dominant) hemisphere stimulation selectively (RUL) reduces verbal memory effects

Factors Worsening Cognitive Effects

• Bilateral > RUL > bifrontal electrode placement
• Sine-wave > brief-pulse > ultra-brief pulse stimulation
• Higher stimulus dose above threshold
• More frequent sessions (3x/week > 2x/week)
• Higher total number of sessions
• Pre-existing cognitive impairment
• Old age
• Concurrent medications (lithium, benzodiazepines)

Management Strategies

ANSWER 13

Psychiatric emergencies: Assessment and management of acute agitation. [5 marks]

Definition

Acute agitation is a state of extreme inner discomfort associated with motor restlessness, verbal and physical aggression, and impulsive behavior. It represents a psychiatric emergency requiring immediate intervention.

Causes (DE-ESCALATION-FAST mnemonic for differential)

• Psychiatric: Acute psychosis (schizophrenia, mania), substance intoxication or withdrawal, delirium, dementia, PTSD, personality disorder crisis
• Medical/Organic: Head injury, hypoglycemia, hypoxia, thyroid storm, seizure (postictal), CNS infection, anticholinergic toxidrome, serotonin syndrome, NMS, hepatic encephalopathy

Assessment

1. Ensure staff safety first (stand-off, no back to wall, exit available)
2. Rapid physical assessment (vital signs, neurological, capillary blood glucose)
3. Brief psychiatric history from collateral if patient not cooperating
4. Identify likely cause (psychiatric vs organic)
5. STAMP (Staring, Tone of voice, Anxiety, Mumbling, Pacing), early agitation signs

Management

Step 1: Verbal De-escalation

• Calm, non-threatening tone and body language
• Acknowledge distress; validate feelings
• Offer choices (oral medication, calm environment)
• Remove audience and reduce stimulation
• Limit-setting: clear, non-punitive

Step 2: Oral Medication (if de-escalation insufficient)

Step 3: Intramuscular Medication (if oral refuses/not possible)

Step 4: Restraint and Seclusion (only if medication insufficient and imminent danger)

• Must follow institutional protocols and MHCA humane treatment provisions
• Document clearly: reason, duration, monitoring
• Reassess frequently; discontinue as soon as safe

Step 5: Reassess and Treat Underlying Cause

• Once agitation controlled: full assessment of underlying cause
• Initiate definitive treatment

ANSWER 14

NMS: Diagnosis and management. [5 marks]

Definition

Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs (or dopamine-blocking agents) characterized by hyperthermia, muscle rigidity, autonomic instability, and altered consciousness.

Causes

• All antipsychotics (FGAs > SGAs; haloperidol most implicated)
• Metoclopramide, prochlorperazine, droperidol
• Abrupt withdrawal of dopaminergic drugs in Parkinson's disease

Clinical Features: "FEVER" mnemonic

• Fever (hyperthermia, often >38.5°C; can reach 41°C)
• Encephalopathy (altered consciousness, confusion to coma)
• Vital instability (tachycardia, labile BP, diaphoresis, tachypnea)
• Elevated CPK (>1000 U/L; often massively elevated >10,000)
• Rigidity (lead-pipe rigidity, diffuse)

Additional: elevated WBC (leukocytosis), elevated liver enzymes, elevated creatinine (myoglobinuria → renal failure)

Investigations

• CPK (creatine phosphokinase), hallmark; should be checked in any suspected case
• Full metabolic panel, LFTs, renal function
• Urine myoglobin (risk of renal failure)
• Blood cultures (exclude sepsis)
• CT head if altered consciousness with focal signs
• Lumbar puncture if CNS infection not excluded

Management

1. Stop the causative drug immediately

2. Supportive care (ICU):

• IV hydration (prevent renal failure from rhabdomyolysis)
• Temperature control (cooling blankets, paracetamol, avoid aspirin)
• Airway management (intubation if severe)
• Monitoring (cardiac, renal, neurological)
• Thromboprophylaxis (risk of DVT)

3. Specific pharmacological treatment:

• Dantrolene 1–2.5 mg/kg IV every 6 hours (muscle relaxant, reduces rigidity and hyperthermia; blocks sarcoplasmic reticulum Ca2+ release)
• Bromocriptine 2.5–5 mg TID orally (dopamine agonist, addresses the dopaminergic mechanism)
• Amantadine (alternative dopamine agonist)
• Lorazepam IV for agitation and catatonic features

4. ECT:

• Indicated for severe/refractory NMS, especially when catatonic features are prominent
• Should not be delayed if patient deteriorating
• Effective via dopaminergic normalization mechanism

5. Resume antipsychotic:

• Wait minimum 2 weeks after resolution
• Use an SGA (lower NMS risk) at lowest effective dose
• Monitor closely

ANSWER 15

Teratogenicity of mood stabilizers in pregnancy. [5 marks]

General Principles

Psychotropic drugs taken during the first trimester carry the highest teratogenic risk (organogenesis occurs weeks 4–10). However, untreated severe psychiatric illness also carries fetal risks (prematurity, intrauterine growth restriction, substance use, perinatal complications). A risk-benefit discussion with the patient is essential.

Valproate (Highest Risk)

Lithium

Carbamazepine

Lamotrigine

Mnemonics & Memory Tricks

Sources: Kaplan & Sadock 12th ed., APA ECT Task Force, MHCA 2017, Stahl's 5th ed.

MNEMONIC 1

ECT Indications: "SAD CAMP"

MNEMONIC 2

Pre-ECT Workup: "CIBLESS"

Bonus additions: Chest X-ray, cognitive baseline (MMSE).

MNEMONIC 3

ECT Contraindications: "PARIS"

MNEMONIC 4

Drugs to Withhold Before ECT: "BLAST"

MNEMONIC 5

Postpartum Disorder Timeline: "3 Bs in Order"

Swipe to compare →

MNEMONIC 6

Edinburgh Postnatal Depression Scale (EPDS) Domains: "A2 L2 G2 C S"

Total: 10 items, 0–30 score. Cutoff: ≥10–13 depending on guideline.

Simplified version: "The EPDS has 10 items: 2 anhedonia + 3 anxiety + 2 low mood + 1 guilt + 1 sleep + 1 self-harm = 10."

MNEMONIC 7

Teratogenic Drugs in Psychiatry: "VaLCaP"

Order by risk: Valproate > Carbamazepine > Lithium > Lamotrigine > Paroxetine

MNEMONIC 8

Breastfeeding-Safe Drugs: "SOn PHONe" (Safe Ones PHarmacologically)

Simplified: Sertraline (antidepressants), Olanzapine (antipsychotics), Carbamazepine + Valproate (mood stabilizers, low transfer), Lorazepam short-term (BZDs).

MNEMONIC 9

NMHP / DMHP Components: "STRIDE"

Core team: Psychiatrist + Clinical Psychologist + Psychiatric Social Worker + Psychiatric Nurse (1 each per district).

MNEMONIC 10

Postpartum Psychosis: Organic Causes to Exclude, "SETS WE"

Also: Cortical vein thrombosis (CVT), headache, focal signs, MRI diagnosis.

MNEMONIC 11

ECT Cognitive Side Effects: Spectrum and Management, "RAPID AR"

MNEMONIC 12

rTMS Parameters for Depression: "LEFT 10 120 3K"

Additional: 20–30 sessions total, 5 days/week, over 4–6 weeks.

Theta burst: 3 pulses at 50 Hz, repeated at 5 Hz, iTBS = 600 pulses in 3 minutes.

MNEMONIC 13

NMS Features: "FEVER"

Management: Stop antipsychotic → ICU → IV fluids → Dantrolene → Bromocriptine → ECT if severe/refractory.

MNEMONIC 14

Telemedicine Schedule X Prohibition: "BOSS Can't Text"

All Schedule X drugs = controlled substances under Drugs and Cosmetics Act → cannot be prescribed via telemedicine under MoHFW 2020 guidelines.

MNEMONIC 15

ECT Electrode Placement: "BRightF", Going from Most to Least Cognitive Risk

Additional memory aid:

• RUL = Non-dominant hemisphere = less verbal memory impact
• Bilateral = Both hippocampi hit = more amnesia
• d'Elia position = RUL landmark (right temporal + vertex)
• Lancaster position = Bilateral landmark (3–4 cm above zygoma-auricular midpoint, bilateral)

MNEMONIC 16

EPDS Cutoff Quick Reference: "10, 13, 0"

MNEMONIC 17

Hale's Lactation Risk Categories: "Safest to Scariest"

MNEMONIC 18

Organic Causes of Acute Agitation: "HIDE + MAST"

SUMMARY TABLE: All Mnemonics at a Glance

High-Yield Comparisons

Sources: Kaplan & Sadock 12th ed., APA ECT Task Force 3rd ed., MHCA 2017, Stahl's 5th ed., Telemedicine Practice Guidelines 2020

TABLE 1

Bilateral vs Right Unilateral vs Bifrontal ECT

Swipe to compare →

TABLE 2

Brief-Pulse vs Ultra-Brief Pulse Stimulation

TABLE 3

Baby Blues vs Postpartum Depression vs Postpartum Psychosis

TABLE 4

ECT vs rTMS vs tDCS

TABLE 5

Thiopentone vs Propofol for ECT Anaesthesia

TABLE 6

Modified vs Unmodified ECT

TABLE 7

Telepsychiatry vs In-Person Psychiatry

TABLE 8

NMHP vs DMHP

TABLE 9

ECT Anesthesia Options: Full Comparison

TABLE 10

Postpartum Psychosis vs Postpartum Blues vs Bipolar Disorder First Episode (Differential Diagnosis Comparison)

PYQ Frequency Analysis

Sources: PG exams MD Psychiatry question papers (compiled), PG exams entrance PYQs. Pattern analysis based on 17+ years of question data.

SECTION 1: FREQUENCY HEATMAP

Overall Topic Frequency (All Sources Combined)

Swipe to compare →

SECTION 2: QUESTION-BY-QUESTION PYQ LOG

ECT: Indications and Technique

ECT: Consent Under MHCA 2017

ECT: Cognitive Side Effects

Bilateral vs Right Unilateral ECT

ECT in Pregnancy

Postpartum Psychosis

Postpartum Depression and EPDS

Drugs Safe in Breastfeeding

rTMS

Telepsychiatry

DMHP

Modified vs Unmodified ECT

NMS

Teratogenicity

SECTION 3: MARK ALLOCATION PATTERNS

Long Answer (10 marks): ECT & Postpartum Topics

Short Answer (5 marks): Common Patterns

Very Short / One-liner (2–3 marks)

SECTION 4: PREDICTION FOR UPCOMING EXAM CYCLE

Near-Certain (P1: Must Prepare Fully)

1. ECT indications and technique (10 marks), appears almost every cycle
2. ECT consent under MHCA 2017 (5 marks), mandatory post-2018
3. Postpartum psychosis (10 marks), high-frequency clinical topic
4. Drugs safe in breastfeeding (5 marks), evergreen clinical question
5. Cognitive side effects of ECT (5 marks), consistently tested

Very Likely (P2: Prepare Thoroughly)

1. Bilateral vs RUL ECT (5 marks), comparison format
2. EPDS (5 marks), postpartum psychiatry anchor
3. rTMS, mechanism and parameters (5 marks), growing frequency
4. Telepsychiatry (5 marks), post-COVID mandatory addition
5. ECT in pregnancy (5 marks), practical clinical scenario
6. Teratogenicity of mood stabilizers (5 marks), perennial

Possible (P3: Overview Preparation)

1. DMHP structure (5 marks)
2. Modified vs unmodified ECT (5 marks)
3. NMS management (5 marks)
4. Maintenance ECT (3–5 marks)

SECTION 5: ANSWER PLANNING GUIDE

10-Mark Answer Blueprint: ECT Indications and Technique

10-Mark Answer Blueprint: Postpartum Psychosis

SECTION 6: COMMONLY CONFUSED PAIRS (HIGH EXAM RISK)

Quick Review

Sources: Kaplan & Sadock 12th ed., APA ECT Task Force 3rd ed., MHCA 2017, Stahl's 5th ed., Telemedicine Practice Guidelines 2020

Q1. Who introduced ECT, and in what year?

Answer:

Ugo Cerletti and Lucio Bini, Rome, 1938. The original (incorrect) rationale was the supposed biological incompatibility between epilepsy and schizophrenia.

Q2. Name the two conditions most commonly cited as absolute contraindications to ECT.

Answer:

(1) Pheochromocytoma, catecholamine surge during seizure is potentially fatal.

(2) Raised intracranial pressure, seizure further elevates ICP, risking herniation.

The APA technically states there are no absolute contraindications, but these two are universally expected in exam answers.

Q3. What is the minimum adequate motor seizure duration in the isolated limb technique?

Answer:

≥25 seconds (motor). EEG criterion: ≥20–25 seconds with postictal suppression. Both motor AND EEG adequacy should be confirmed. Seizures shorter than 25 seconds (motor) are considered inadequate regardless of clinical appearance.

Q4. What dose of ECT stimulus is required for right unilateral (RUL) ECT to achieve efficacy equivalent to bilateral ECT?

Answer:

6x the seizure threshold. At lower doses (e.g., 2.5x), RUL ECT is clearly inferior to bilateral ECT in antidepressant efficacy. This dose-response relationship is the single most-tested numerical fact about electrode placement.

Q5. What does Section 95 of the Mental Health Care Act 2017 state about ECT?

Answer:

ECT is absolutely prohibited for all persons under 18 years of age. There are no exceptions, not even in life-threatening emergencies. This is one of the few absolute prohibitions in the entire Act.

Q6. Under MHCA 2017, when may ECT be administered without the patient's informed consent?

Answer:

Only in a genuine life-threatening emergency, and only after a second psychiatrist certifies the necessity. Full documentation is mandatory. As soon as the patient regains decision-making capacity, they must be informed of what was done and why.

Q7. Name the induction agent used in ECT that raises the seizure threshold and may shorten seizure duration.

Answer:

Propofol. Because it raises seizure threshold, a higher stimulus energy may be needed when propofol is used compared to thiopentone. It offers advantages of smoother recovery and antiemetic effect, but may compromise seizure quality at standard doses.

Q8. What is the purpose of the isolated limb technique in ECT?

Answer:

A blood pressure cuff is inflated above systolic pressure on one forearm or ankle before succinylcholine is injected. The muscle relaxant cannot reach that limb, so its muscles contract visibly during the seizure. This allows direct visual monitoring of motor seizure onset, quality, generalization, and duration.

Q9. Name the three electrode placements used in ECT, from highest to lowest cognitive side effect burden.

Answer:

(1) Bilateral (bitemporal), highest cognitive effects, highest efficacy, fastest response.

(2) Bifrontal, intermediate.

(3) Right unilateral (RUL), least cognitive effects (stimulates non-dominant hemisphere), equivalent efficacy only at 6x seizure threshold.

Q10. What is the difference between brief-pulse and ultra-brief pulse ECT?

Answer:

Brief-pulse: pulse width 0.5–2.0 ms; current standard for bilateral ECT; moderate cognitive effects.

Ultra-brief pulse: pulse width ≤0.3 ms (typically 0.2 ms); significantly fewer cognitive effects, especially retrograde amnesia; slightly lower efficacy in some populations; best paired with RUL placement. Sine-wave ECT (continuous, no pulse) is now completely abandoned due to excessive cognitive side effects.

Q11. State the onset, prevalence, and duration of postpartum blues, postpartum depression, and postpartum psychosis.

Answer:

Swipe to compare →

Q12. What is the cardinal clinical feature that distinguishes postpartum psychosis from other postpartum disorders and from first-episode schizophrenia?

Answer:

Confusion and disorientation, often the first sign in PPP, disproportionate to the clinical picture. Combined with rapid mood fluctuations within hours (elation to despair), this gives PPP a delirious-manic quality not seen in baby blues, PPD, or typical schizophrenia. Always exclude organic causes (sepsis, eclampsia, thyroid, electrolytes) when confusion is prominent.

Q13. Name the six organic causes to exclude before diagnosing postpartum psychosis (use SETS WE).

Answer:

• S, Sepsis (puerperal)
• E, Eclampsia
• T, Thyroid (storm or autoimmune thyroiditis)
• S, Sheehan's syndrome (pituitary infarction)
• W, Wernicke's encephalopathy (thiamine deficiency)
• E, Electrolyte disturbance (Na+, Mg2+, Ca2+)

Also: cortical vein thrombosis (headache + focal signs → MRI).

Q14. What is the first-line antidepressant for a breastfeeding mother with postpartum depression, and why?

Answer:

Sertraline (Hale's LRC: L2). It has the most extensive safety data in breastfeeding: infant serum levels are undetectable or negligible in most studies, no adverse neonatal outcomes documented, and it is effective for PPD. Fluoxetine (L3) should be avoided due to its long half-life and accumulation of the active metabolite norfluoxetine in infant serum.

Q15. What are the EPDS cutoff scores, and what is special about Item 10?

Answer:

Score range: 0–30. Cutoff for probable PPD: ≥10 (NICE guidelines; some use ≥13, know both).

Item 10 asks specifically about thoughts of self-harm or suicide. Any score >0 on Item 10 requires immediate clinical risk assessment regardless of the total EPDS score. It is a non-negotiable safety screen item independent of the total score.

Q16. Name three risk factors that increase the likelihood of developing postpartum depression.

Answer:

(Strongest/most testable):

1. Personal history of depression or anxiety, strongest predictor (RR 3–5x)
2. Personal history of PPD, 25–50% recurrence rate with subsequent deliveries
3. Poor social support / relationship difficulties

Others: antenatal depression, birth trauma, premature/ill infant, history of PMDD, domestic violence.

Q17. What is the bipolar disorder link with postpartum psychosis?

Answer:

PPP is strongly linked to Bipolar I disorder, 50–80% of women with PPP are subsequently diagnosed with bipolar disorder. PPP may represent the first manifestation of Bipolar I in many patients. Women with a confirmed bipolar diagnosis have a 25–50% risk of PPP with each delivery without prophylaxis. Lithium started immediately post-delivery significantly reduces this risk.

Q18. State the mechanism of action of rTMS and the standard parameters for treating depression.

Answer:

Mechanism: Rapidly alternating magnetic field from a scalp coil induces focal electrical currents in underlying cortex (Faraday's law). High-frequency (≥10 Hz) = excitatory; low-frequency (≤1 Hz) = inhibitory. For depression: high-frequency left DLPFC stimulation restores hypoactive prefrontal activity and normalizes fronto-limbic connectivity.

Parameters: Left DLPFC target; 10 Hz; 120% resting motor threshold; 3,000 pulses/session; 20–30 sessions over 4–6 weeks (5 days/week).

Q19. What is theta burst stimulation and what is its main clinical advantage?

Answer:

A patterned rTMS protocol: 3 pulses at 50 Hz, repeated at 5 Hz.

Intermittent TBS (iTBS): excitatory, 600 pulses delivered in just 3 minutes (vs 37 minutes for standard 10 Hz). FDA-approved; non-inferior to standard rTMS in RCTs. The main advantage is drastically reduced session duration, improving patient acceptance and clinic throughput.

Q20. What drugs cannot be prescribed via telemedicine under the Telemedicine Practice Guidelines 2020 (India)?

Answer:

Schedule X drugs, these are controlled substances under the Drugs and Cosmetics Act:

• Benzodiazepines (diazepam, clonazepam, lorazepam, alprazolam)
• Opioids (morphine, codeine, tramadol-containing Schedule X formulations)
• Psychostimulants (methylphenidate, amphetamines)
• Sedative-hypnotics (zolpidem)

Schedule H and H1 drugs (antidepressants, antipsychotics, mood stabilizers) can be prescribed via telemedicine.

Q21. Name the DMHP pilot site and year, and state the core team at district level.

Answer:

Pilot: Bellary, Karnataka, 1996.

Core district team (1 each):

• Psychiatrist
• Clinical Psychologist
• Psychiatric Social Worker
• Psychiatric Nurse
• Case Registry Officer

India has approximately 0.3 psychiatrists per 100,000 population, far below WHO's recommended 1 per 10,000.

Q22. Describe maintenance ECT: what is the standard tapering schedule?

Answer:

Maintenance ECT is used for relapse prevention after a successful acute ECT course.

Standard tapering schedule:

• Weeks 1–4: Once weekly
• Weeks 5–8: Fortnightly
• Month 3 onwards: Monthly (ongoing if needed)

Evidence: Kellner et al. (NEJM, 2006) showed M-ECT + nortriptyline was superior to nortriptyline alone in preventing relapse. M-ECT is evidence-based, not experimental. Serial cognitive monitoring is mandatory during M-ECT.

Q23. What are the clinical features of NMS? Use the FEVER mnemonic.

Answer:

• F, Fever (hyperthermia >38.5°C, can reach 41°C)
• E, Encephalopathy (altered consciousness, confusion to coma)
• V, Vital sign instability (tachycardia, labile BP, diaphoresis, tachypnea)
• E, Elevated CPK (>1000 U/L, often massively elevated) + elevated WBC
• R, Rigidity (lead-pipe, diffuse, cardinal sign)

Management: Stop antipsychotic → ICU → IV fluids → Dantrolene → Bromocriptine → ECT if severe/refractory.

Q24. What modifications are required when administering ECT to a pregnant patient?

Answer:

Key modifications:

1. Obstetric anaesthesiologist present
2. Fetal heart rate monitoring (from ≥16 weeks)
3. Uterine contraction monitoring
4. Left lateral tilt of operating table (aortocaval decompression)
5. Sodium citrate 30 mL orally before each session (aspiration risk)
6. Consider intubation if airway concerns
7. Tocolytic on standby (premature labour)
8. Succinylcholine dose adjustment (reduced plasma cholinesterase in pregnancy)
9. Minimize hyperventilation (fetal hypoxia risk)
10. Pre-procedure IV hydration

ECT is preferred over most psychotropics in first trimester for severe psychiatric illness.

Q25. Which mood stabilizer carries the highest teratogenic risk, and what are its specific fetal effects?

Answer:

Valproate (sodium valproate), highest risk of any mood stabilizer.

Specific risks:

• Neural tube defects: 1–4% (spina bifida, anencephaly)
• Cardiac defects (VSD, ASD)
• Fetal valproate syndrome (craniofacial features: thin upper lip, broad nasal bridge, epicanthal folds)
• Cognitive deficit: IQ reduction of 7–9 points vs matched controls (dose-dependent)
• Autism spectrum disorder: RR 3–5x background rate

Action: Avoid in all women of childbearing potential unless no other option. If essential, use lowest effective dose + folic acid 5 mg/day + detailed anomaly scan + informed consent.

Q26. Compare NMS and serotonin syndrome on three key axes.

Answer:

Additional: Both cause hyperthermia + altered consciousness. NMS: elevated CPK, no clonus. SS: clonus is hallmark, less CPK elevation. Treatment: NMS → dantrolene + bromocriptine. SS → stop serotonergic drugs + cyproheptadine (5-HT2A antagonist).

Q27. What is Hale's L2 category, and name two L2 antidepressants and one L2 antipsychotic safe in breastfeeding?

Answer:

L2 = Safer, limited adverse effects observed in controlled studies; probably compatible with breastfeeding.

L2 antidepressants: Sertraline (first choice), Paroxetine, Nortriptyline.

L2 antipsychotic: Olanzapine (preferred in breastfeeding), Haloperidol.

Avoid: Fluoxetine (L3, accumulates), Clozapine (L3–4, agranulocytosis risk in infant).

Q28. Describe the hub-and-spoke telepsychiatry model as implemented by PG exams.

Answer:

The PG exams model uses:

• Hub: PG exams, Bengaluru, provides specialist psychiatric consultation via video
• Spokes: District hospitals and primary health centres across rural Karnataka
• First contact: Trained ASHA workers and PHC doctors identify and initially manage patients locally; complex cases are escalated to the hub via video consultation
• Validated in: Rural Karnataka; adopted as a national reference model for telepsychiatry
• Outcome: Significantly improved access to specialist care without requiring tertiary-centre travel; reduced treatment gap in underserved areas

Q29. What is PMDD and what is its first-line pharmacological treatment?

Answer:

Premenstrual Dysphoric Disorder (PMDD), DSM-5 diagnosis. 5+ symptoms in the final week before menses, improving within days of menstrual onset, minimal/absent post-menstruation. Core symptoms: affective lability, irritability, depressed mood, anxiety. Prevalence: 3–8% of women of reproductive age. Must be documented prospectively over 2 menstrual cycles (DRSP scale).

Pathophysiology: Abnormal CNS sensitivity to normal cyclical fluctuations in allopregnanolone (progesterone metabolite), not a hormone deficiency.

First-line treatment: SSRIs, sertraline, fluoxetine (Sarafem), escitalopram. Can be given continuously or only in the luteal phase (day 14 to menses onset), luteal phase dosing is effective and reduces side effects.

Q30. State three key limitations of telepsychiatry compared to in-person psychiatry that are clinically significant.

Answer:

(Most exam-relevant three):

1. Cannot perform physical examination, cannot assess extrapyramidal side effects, tardive dyskinesia, tremors, or monitor vital signs accurately. Critical for patients on antipsychotics or lithium.

1. Emergency management is limited, cannot ensure physical safety, remove means of self-harm, or directly call emergency services to the patient's location. Safety planning is less effective remotely.

1. Schedule X drugs cannot be prescribed, benzodiazepines, opioids, and stimulants are prohibited under MoHFW Telemedicine Practice Guidelines 2020. This significantly limits acute agitation management and ADHD prescribing via telemedicine.

Additional valid answers: digital divide (rural/elderly), confidentiality risk (third parties at home), non-verbal cue limitations.

RAPID-FIRE SINGLE-LINE RECALL